Antares Pharma (AIS) Reports a Q3 Loss In-line W/Estimates
More News related to AIS
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Antares Pharma Enters into License and Asset Purchase Agreements with Ferring
- Antares Pharma (AIS) Reports a Q3 Loss In-line W/Estimates
- Antares Pharma Reports Third Quarter 2009 Financial and Operating Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
More News related to Earnings
- Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
- Bove Says US Banking System, Dollar to Benefit from Dubai Crisis
- Broadpoint.AmTech Says Solar Inventory Getting Healthier into Year-end
- UBS Maintains a Neutral rating on American Eagle Outfitters (AEO); Lowers Estimates Through 2011
- Barclays Reiterates an 'Overweight' on Deere (DE); Adjusts Estimates & PT
Antares Pharma, Inc. (NYSE: AIS) reports a Q3 loss of $0.04, in-line with the analyst estimate of ($0.04). Revenue for the quarter was $2.0 million, which compares to the estimate of $1.89 million.
Related Categories
EarningsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
